Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）

Study Overview
=================
Brief Summary
-----------------
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.

Detailed Description
-----------------
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.

Official Title
-----------------
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators

Conditions
-----------------
Infective Endocarditis

Intervention / Treatment
-----------------
* Other: Observational; No Interventions were given.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clinically confirmed infective endocarditis Exclusion Criteria: Patients refuse to sign informed consent form Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infective endocarditis group<br>Patients diagnosed with infective endocarditis. | Other: Observational; No Interventions were given.<br>* Observational; No Interventions were given.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the incidence of MACCE | MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse thrombus complications | Adverse thrombus complications including systemic embolism, infected aneurysm, splenic abscess, etc. | 5 years after the enrollment. | 
| Change in the incidence of infection recurrence | Diagnosis of infective endocarditis by clinical guidelines, which will be assessed from medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 
| Change in the incidence of myocardial infarction | Myocardial infarction, diagnosed by clinical doctors, will be assessed from medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 
| Change in the incidence of stroke | Stroke, diagnosed by clinical doctors, will be assessed from medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 
| Change in the incidence of vessel revascularization | Vessel revascularization, diagnosed by clinical doctors, will be assessed from medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 
| Change in the incidence of all-cause death | All-cause death, diagnosed by clinical doctors, will be assessed from medical records. | 1, 3, 6 months and 1, 2, 3, 5 years after enrollment. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infective Endocarditis, Prognosis, Major Adverse Cardiac and Cerebrovascular event